SLC2A1 and fatty liver disease: Trehalose was reported to inhibit members of the solute carrier 2 A (SLC2A) family (also referenced as the glucose transporter, or GLUT family) of glucose transporters and trehalose-mediated inhibition of glucose transport induced AMPK (adenosine 5′-monophosphate-activated protein kinase)-dependent autophagy regression of hepatic steatosis in vivo [27].